ABCL (38) INDV (51) LEGN (64) LQDA (36) ⌘ Pro Terminal →

Edgewise Therapeutics Inc. (EWTX) — RQD Stock Rating Cockpit

$38.90 -0.03% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $38.82

Edgewise Therapeutics Inc. (EWTX) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $4.23B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on EWTX Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is EWTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Edgewise Therapeutics Inc. (NASDAQ: EWTX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $38.90 (-0.03% 1D, market cap $4.23B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Active quantitative signal LIQUIDITY_TAILWIND (BEARISH, conviction undefined/100) notes: undefined.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does EWTX compare to ABCL and INDV in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), EWTX carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -31.9%. By comparison, ABCL (AbCellera Biologics Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -20.5%, cap $4.24B) and INDV (Indivior Pharmaceuticals Inc.) posts a D grade (51/100 RQD, P/E 19.8x, ROIC 62.2%, cap $4.16B). Among the 5-stock peer group, INDV leads on earnings multiple (19.8x) while INDV leads on capital efficiency (62.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for EWTX?

▼

Per EWTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001710072), Edgewise Therapeutics Inc. generated $0 in revenue, -$167.8K in net income, and -$144.1M in free cash flow against $552.6M in total assets and $13.7M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $38.82 (-0.20%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.2% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-7.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for EWTX)Realized 20D OHLCV Swing Band: ±9.9%

Deterministic 5-Pillar Attribution (41/100 Composite)

🔍 WHY EWTX SCORES 41/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (32% of score)

Altman Z-Score 26.00 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Whale & Options Positioning+10/20 pts (24% of score)

20D Institutional Volume Accumulation (±9.9% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$36.28+9.6% Next Q

Q2 (-2Q)

Grade E$39.75-0.6% Next Q

Q3 (-1Q)

Grade E$39.53-1.6% Next Q

Current

Grade D-$38.90-7.2% Hist 90D α

Trajectory: E (33) → D- (41)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a EWTX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While EWTX currently carries a cautious 41/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($41.12) and Max Pain ($40.85) forces dealer call-delta covering toward $50.94.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $EWTX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “EWTX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 41%NO 59%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

45.830 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

26.00>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

3 / 99-Pt Accounting

52-WEEK LASER RANGE70% OF RANGE

L: $17$38.90H: $49

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 5 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 13 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: D+RQD 23 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on EWTX

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (25)

-31.9% ROIC with 42.0% gross margin and -3.41% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (65)

Altman-Z 26.00 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (38)

13/40 institutional & smart-money positioning score with 10/20 macro alignment.

Bull Case: Why Buyers Like EWTX

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring EWTX)

✓Walkthrough of EWTX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

EWTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +23.69%📐 HORIZONTAL RANGE

2026-11-02O $40.49H $40.49L $38.90C $38.90VOL 1.21M

RES: $51.35SUP: $35.26SMA50: $41.12SMA200: $36.39

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

EWTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 EWTX Butterfly Map → + Track EWTX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

18.7%/yr Implied 5Y Growth

vs. -1.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on EWTX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for EWTX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for EWTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (EWTX)

Health Care Rank #491 of 1016 ⚔️ ABCL vs EWTX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (EWTX vs. ABCL, INDV, LEGN, LQDA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Edgewise Therapeutics Inc. (EWTX) ranks #491 by composite RQD confidence (41/100, grade D-) and #177 by equity capitalization ($4.23B). Within this direct 5-issuer industry benchmark cohort, INDV leads on earnings valuation at 19.8x trailing P/E, while INDV leads on capital efficiency and profitability with 62.2% ROIC and 80.2% gross margin. LEGN currently holds the highest overall quantitative score in the immediate peer group at 64/100 (C) compared with EWTX at 41/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
EWTX ACTIVE Edgewise Therapeutics Inc.	D-	41/100	—	—	-31.9%	-0.03%	$4.23B	Benchmark Subject
ABCL AbCellera Biologics Inc.	D-	38/100	—	—	-20.5%	-6.19%	$4.24B	/abcl-vs-ewtx →
INDV Indivior Pharmaceuticals Inc.	D	51/100	19.8x	80.2%	62.2%	+0.34%	$4.16B	/indv-vs-ewtx →
LEGN Legend Biotech Corporation	C	64/100	32.8x	—	9.9%	-3.00%	$4.34B	/legn-vs-ewtx →
LQDA Liquidia Corporation	D-	36/100	—	—	-12.6%	+0.16%	$4.03B	/lqda-vs-ewtx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001710072

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Edgewise Therapeutics Inc. (EWTX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$167.8K, operating cash flow of -$143.8M, and free cash flow of -$144.1M (-30.6% YoY). On the balance sheet, EWTX closed FY2025 with $552.6M in total assets against $13.7M in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$167.8K	-$143.8M	-$144.1M	$552.6M	$13.7M
FY2024 (FY)	2024-12-31	$0	-$133.8K	-$109.0M	-$110.3M	$486.8M	$12.4M
FY2023 (FY)	2023-12-31	$0	-$100.2K	-$91.9M	-$91.9M	$2.32B	$543.9M

3. EWTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is EWTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does EWTX compare to ABCL and INDV in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for EWTX?

Where is EWTX trading relative to its 50-day, 200-day, and 52-week technical levels?

EWTX last traded at $38.90 (-0.03% on volume of 967,650 shares), positioning the stock -5.40% below its 50-day simple moving average ($41.12) and +6.90% above its 200-day simple moving average ($36.39). Across its 52-week range of $16.70 to $48.51, EWTX sits at the 69.8% percentile with a 14-day RSI of 45.8 (NEUTRAL RANGE) and an implied next-earnings move of ±9.9% ($35.05 to $42.75).

EWTX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell EWTX stock right now?

Edgewise Therapeutics Inc. (EWTX) currently earns a Roarable Rating of D- (Sell — SELL) with 41/100 RQD Confidence. Stretched risk/reward at current multiples (-32% return on capital) under elevated 10-year interest-rate pressure.

What is EWTX's 12-month price target and RQD AI Jury consensus?

EWTX's 12-month base price target is $35.92 (range $28.02 to $50.94), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: EWTX RQD Cockpit EWTX 12M Forecast EWTX Earnings & Move EWTX Dividends & DRIP EWTX Insiders & 13F EWTX Whale Options EWTX Profit Sankey EWTX News & Why

ROARABLE RATING BRIEF • RQD 41/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

EWTX — Edgewise Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:22:01Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, EWTX scores 41 out of 100, a letter grade of D-, with the verdict "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:

Fundamental Cash Engine: 5 / 20. Per the Roarable RQD rating, this pillar reflects ROIC of -31.9% and an FCF yield of -3.41%. For a prospective investor, this is the weakest pillar: the company is currently consuming cash rather than generating it, so the valuation rests on future expectations rather than current cash returns.
Whale 13F Flow: 10 / 20. Per the Roarable RQD rating, this pillar covers institutional accumulation and options positioning. The score is mid-range; the underlying 13F and options detail is not itemized in the source data.
Insider Conviction: 3 / 20. Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. The low score indicates insider and related-party flow is not providing a strong conviction signal.
Macro Regime Fit: 10 / 20. Per the Roarable RQD rating, this pillar reflects a beta of 1.1 and sector sensitivity. The score indicates moderate, slightly-above-market sensitivity to broad market moves.
Forensic Balance Sheet: 13 / 20. Per the Roarable RQD rating, this pillar reflects an Altman Z-Score of 26, a Piotroski F-Score of 3/9, and a Debt/Equity ratio of 0.02. The low leverage is a relative strength, while the weak Piotroski reading signals limited financial-quality strength.

Investment implications (educational, not personalized advice): the upside case depends on a clean balance sheet and the pipeline's ability to turn expenditure into value, while the valuation tradeoff is that a forward P/E of 25 is being paid for earnings that the trailing data does not yet show (EPS TTM is 0). The primary risk is cash burn: per the SEC financials, free cash flow was negative in each reported period, so continued funding needs are the key second-order concern.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-191.4M	$-0.2M	N/A	$-144.1M	$61.1M	$13.7M
FY 2024	$0.0M	$-158.8M	$-0.1M	N/A	$-110.3M	$41.7M	$12.4M
FY 2023	$0.0M	$-114.4M	$-0.1M	N/A	$-91.9M	N/A	$543.9M

Per the SEC financials, operating losses widened from $-114.4M in FY 2023 to $-191.4M in FY 2025, and free cash flow was negative in all three periods. Gross margin, operating margin of -16.2%, and net margin of 0% are reported in market data, and ROIC is -31.9%. Per the Roarable RQD rating, the Altman Z-Score is 26 and the Piotroski F-Score is 3/9. Debt/Equity is 0.02 per the Roarable RQD rating, and reported debt fell from $543.9M in FY 2023 to $13.7M in FY 2025.

Recent Catalysts & News Wire Analysis

Phase 3 design focus: A Yahoo Finance report headlined that investors are focused on the upcoming Phase 3 design for 7500 in hypertrophic cardiomyopathy, citing RBC.
Analyst reiteration: Investing.com reported H.C. Wainwright reiterated its buy rating on EWTX.
Equity grants: Stock Titan reported two new hires received rights to buy 17,250 shares and awards covering 8,626 more.
Earnings: A TradingView item lists a Q3'26 earnings revenue estimate of 0 USD.
HFpEF expansion: A Yahoo Finance piece questions whether HFpEF expansion redefines the core cardiovascular strategy.
RBC buy rating: The Globe and Mail reported RBC Capital assigned a buy rating.

Risk watch items: the Phase 3 design is the central binary catalyst, and the zero revenue estimate underscores continued dependence on funding. Per the Butterfly Supply-Chain Graph, the proprietary liquidity signal (LIQUIDITY_TAILWIND) carries a macro tailwind score of 28/100 and a bearish direction with severity 83. Its brief states EWTX shows a 2.21x True Net Liquidity elasticity (r = +0.22) with the True Net Liquidity Index at $5,745.73B and a -0.64% 4-week rate of change, with High-Yield OAS at +2 bps. Implication: EWTX is highly sensitive to liquidity conditions, so tightening liquidity is a second-order downside risk.

Open Questions

What is the Phase 3 timeline and trial design for the hypertrophic cardiomyopathy program, and how is it funded?
What is the company's cash runway at the current FY 2025 burn rate, and what financing is planned?
Which products or pipeline assets generate the company's value, and what is the commercial plan?
What explains the sharp reduction in debt from $543.9M in FY 2023 to $13.7M in FY 2025?
What are the analyst consensus rating and price targets, and what do institutional and insider holdings look like?

EWTX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Edgewise Therapeutics Inc. (EWTX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to EWTX Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 11h ago

Edgewise Therapeutics' Investors Focused on Upcoming Phase 3 Design for '7500 in Hypertrophic Cardiomyopathy, RBC Says

Yahoo Finance report covering Edgewise Therapeutics Inc. (EWTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com • 14h ago

H.C. Wainwright reiterates Edgewise Therapeutics stock rating at buy

Investing.com report covering Edgewise Therapeutics Inc. (EWTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 17h ago

Two new Edgewise hires received rights to buy 17,250 shares and awards covering 8,626 more.

Stock Titan report covering Edgewise Therapeutics Inc. (EWTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 20h ago

EWTX Q3'26 Earnings: revenue estimate is 0 USD

TradingView report covering Edgewise Therapeutics Inc. (EWTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 23h ago

Does Edgewise Therapeutics’ (EWTX) HFpEF Expansion Quietly Redefine Its Core Cardiovascular Strategy?

Yahoo Finance report covering Edgewise Therapeutics Inc. (EWTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The Globe and Mail • 1d ago

Edgewise Therapeutics (EWTX) Gets a Buy from RBC Capital

The Globe and Mail report covering Edgewise Therapeutics Inc. (EWTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

Trial Design Update Might Change The Case For Investing In Edgewise Therapeutics Stock (EWTX)

Simply Wall St report covering Edgewise Therapeutics Inc. (EWTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Traders Daily • 1d ago

Why (EWTX) Price Action Is Critical for Tactical Trading

Stock Traders Daily report covering Edgewise Therapeutics Inc. (EWTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

EWTX Bull vs. Bear Conversation Board — What's Your Call at $38.90?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON EWTX 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $34.24 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is EWTX (D- • RQD 41/100) a Buy at $38.91?

Welcome to the EWTX (Edgewise Therapeutics Inc.) Roar Pit. Current RQD Composite is 41/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $31.52 (-19.0%)

Spot @ $38.91

Pump the brakes on EWTX — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on EWTX, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Edgewise Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH 🎯 Target: $45.52 (+17.0%)

Spot @ $38.91

EWTX cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on EWTX, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $38.91 (52-wk range $16.70 - $48.51), any beat on forward guidance forces shorts and underweight funds to chase.